Althea Technologies, Inc., a leading provider of innovative technologies and services for pharmaceutical development and clinical evaluation, and Natural Selection, Inc. (NSI), a leader in the application of sophisticated computational intelligence algorithms to problems in bioinformatics, announced the introduction of a novel lead compound toxicity classification assay employing multiplex gene expression screening paired with neural network analysis.
